Structure-Based Design of Novel Class II c-Met Inhibitors: 1. Identification of Pyrazolone-Based Derivatives

Abstract excerpt

Deregulation of c-Met receptor tyrosine kinase activity leads to tumorigenesis and metastasis in animal models. More importantly, the identification of activating mutations in c-Met, as well as MET gene amplification in human cancers, points to c-Met as an important target for cancer therapy. We have previously described two classes of c-Met kinase inhibitors (class I and class II) that differ in their binding...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Liver physiology and pathology
• Share to PI3K/AKT/mTOR signaling in cancer
• Share to Protein Kinase Regulation and GTPase Signaling